• Cancer therapies MGN1703 and MGN1601 deliver promising study results
  • Start of cooperation with Charité Berlin and Max Delbrück Centrum
  • Successful capital increases create solid financial basis

In the first nine months of the current fiscal year, MOLOGEN AG achieved several important objectives, particularly in the area of research and development. The clinical studies of both product candidates, MGN1703 (colorectal cancer) and MGN1601 (renal cancer) exceeded all expectations. The successful conclusion of preclinical work on the leishmaniasis vaccine MGN1331 and the start of the cooperation with Charité Berlin and the Max Delbrück Centrum for the clinical testing of an immunotherapy against malignant melanoma based on the

®

technology developed by MOLOGEN represented other positive milestones in the current reporting period. Furthermore, thanks to the capital increases carried out in April and June of 2012, MOLOGEN was able to more than triple the cash and cash equivalents, to 25.2 million euros, by the end of the third quarter.

The current studies on MOLOGEN compounds MGN1703 and MGN1601 delivered outstanding scientific results. An initial evaluation of the colorectal cancer study with MGN1703 has already resulted in a statistically significant demonstration that, in a subpopulation, the median progression-free survival of 5.8 months was more than double that of the placebo group. Progression-free survival describes the time period during which a cancer does not progress any further and is the primary endpoint of the study. The hazard ratio for this population is 0.39. That means that the risk of renewed tumor progression in patients treated with MGN1703 was less than half that of the placebo group. The evaluations of the MGN1703 colorectal cancer study, which were presented to this year's congress of the European Society for Medical Oncology (ESMO), generated great interest among industry professionals, and particularly among pharmaceutical companies. MOLOGEN has thus further strengthened the activities relating to the licensing of MGN1703.  Furthermore, MOLOGEN has applied for a phase II study, in order to confirm the efficacy of MGN1703 in lung cancer as well. The preparations for this study are being moved forward intensively.

The newest data from the renal cancer study with MGN1601, which was also presented at the ESMO congress, is extremely promising. In patients who were able to completely finish the prescribed therapy regimen of the study, it shows an exceedingly clear survival advantage over patients who had to terminate the treatment prematurely due to their severe cancer.

During the reporting period, MOLOGEN also moved forward with the activities in the area of research and development for both vaccine candidates, MGN1331, for the treatment of Leishmaniasis, and MGN1333, for the treatment of hepatitis B. The preclinical work on vaccine candidate MGN1331 has since been finished and showed outstanding test results.

Results of operations developing according to plan
In the first three quarters of 2012, MOLOGEN AG achieved total revenue of 0.1 million euros (9M 2011: 0.1 million euros) and other operating income of 0.2 million euros (9M 2011: 0.5 million euros). As expected, the net loss for the reporting period increased correspondingly, from 5.0 million euros in the first nine months of 2011 to the current 5.7 million euros. The primary factor driving this was the increase in research and development activities, particularly in the area of clinical studies.

As of September 30, 2012, MOLOGEN AG had cash and cash equivalents in the amount of 25.2 million euros (12/31/11: 7.5 million euros). The majority of the cash and cash equivalents originate from the two successful capital increases that MOLOGEN carried out in 2012.

"Since we were able to strengthen the financial basis of the company immensely through two capital increases in recent months, MOLOGEN now presents itself as a very solidly financed company with great scientific and economic potential," said Jörg Petraß, Chief Financial Officer of MOLOGEN AG.

About MOLOGEN AG
MOLOGEN AG, a German biopharmaceutical company with headquarters in Berlin specializes in the research and development of innovative medications on the basis of DNA structures. The activities focus on numerous product developments which are relevant to the immune system; on the one hand vaccines against infectious diseases and on the other hand cancer medications. MOLOGEN AG is globally one of the few biotechnology companies with well tolerated DNA-based cancer treatment in the clinical development phase.

The stocks of MOLOGEN AG (ISIN DE0006637200) are listed in the Prime Standard of the German stock exchange.

Memberships in associations:
Biotechnologieverbund Berlin-Brandenburg (bbb) e.V. | BIO Deutschland e.V.  |  DECHEMA - Society for chemical technology and biotechnology e.V.  |  German industrial association of biotechnology (DIB)  |  Association for the Promotion of Science and Humanities in Germany  |  Association of German biotechnology companies (VBU)  |  Association of researching manufacturers of pharmaceuticals e.V. (VFA)  |  Association of the chemical industry e.V. (VCI)

®, ® and MOLOGEN® are registered trademarks of MOLOGEN AG.

MOLOGEN AG

PRESS SERVICE
Prof. Peter W. Huebner
Head of Corporate Communications
Tel:  +49 - 30 - 84 17 88 - 38
Fax:  +49 - 30 - 84 17 88 - 50
huebner@mologen.com

INVESTOR RELATIONS
Joerg Petrass
Tel:  +49 - 30 - 84 17 88 - 13
Fax:  +49 - 30 - 84 17 88 - 50
investor@mologen.com

External Investor Relations
Kirchhoff Consult AG
Sebastian Bucher
Tel:  +49 - 40 - 60 91 86 - 18
Fax:  +49 - 40 - 60 91 86 -16
sebastian.bucher@kirchhoff.de

Note about risk for future predictions
Certain information in this report contains forward-looking statements or the corresponding statements with negation or versions deviating from this or comparable terminology. These are described as forward-looking statements. In addition, all of the information given here that refers to planned or future results of business areas, key financial figures, developments of the financial situation or other financial figures or statistical data, is to be understood as such forward-looking statements. The company points out to investors that they should not rely on these forward-looking statements as predictions about actual future events. The company is not obligated and refuses to accept any liability for the forward-looking statements and has no obligation to update such statements in order to accurately reflect the current situation.

distributed by